Getwell Mesna Injection contains Mesna 100 mg/ml, a uroprotective agent used primarily to prevent hemorrhagic cystitis caused by the administration of certain chemotherapeutic agents such as cyclophosphamide and ifosfamide. Mesna acts by binding to and detoxifying the urotoxic metabolites, particularly acrolein, thereby protecting the bladder epithelium from damage. This injection is indicated as a prophylactic measure during chemotherapy regimens that pose a risk of bladder toxicity. Administered intravenously, Getwell Mesna Injection is typically given concomitantly with or shortly after the chemotherapeutic agent to ensure effective detoxification within the urinary tract. Dosage and duration of therapy should be individualized based on the chemotherapy protocol and patient-specific factors, including renal function. Common adverse effects are generally mild and may include nausea, vomiting, and hypersensitivity reactions. Careful monitoring is recommended during treatment to detect any signs of adverse effects or inadequate uroprotection. Getwell Mesna Injection should be used under strict medical supervision, with attention to proper dilution and administration techniques to minimize local irritation. It is contraindicated in patients with known hypersensitivity to Mesna or any of its components. This product is a vital adjunct in oncology supportive care to reduce chemotherapy-induced bladder toxicity.